sibutramine administered once daily for 3 months to 2 years have been demonstrated in obese patients in several controlled clinical trials. [25] [26] [27] [28] [29] [30] [31] The primary end point of this study was to assess the efficacy and safety of sibutramine (20 mg given once daily for 24 weeks) to promote weight loss and improve lipid profiles in overweight and obese patients with high serum triglyceride and low serum HDL-C levels.
Material and methods

Design
This multicenter (13 study centers), randomized, doubleblind, placebo-controlled, parallel-group study consisted of a 3-week single-blind placebo run-in period followed by a 24-week double-blind treatment period in which eligible patients were randomized in a 1:1 ratio to receive sibutramine or placebo. The initial dosage of sibutramine (5 mg once daily) was titrated upward in 5-mg increments every 2 weeks to 20 mg at week 6. The 20-mg dosage was administered for the remainder of the 24-week treatment period. Patients were instructed to adhere to a step I American Heart Association diet consisting of 30% fat (10% from saturated fat), 55% carbohydrates, and 15% protein. Caloric intake was limited to 1500 kcal/d for women and 1800 kcal/d for men.
Patients
Screening for patients was ongoing and constant and was performed through public screenings and visits to specialized lipid clinics that included large patient databases. The exact number of screened patients is therefore unavailable. A total of 322 patients were enrolled and randomized to receive sibutramine (n = 162) or placebo (n = 160). The study design was approved by the Institutional Review Board of each facility, and informed written consent was obtained from individuals before study entry. Patients had a body mass index (BMI) ≥27.0, serum triglyceride levels ≥250 mg/dL and ≤1000 mg/dL, and serum HDL-C levels ≤45 mg/dL (women) or ≤40 mg/dL (men) at the screening visit. Female patients had to have been surgically sterilized, at least 2 years postmenopausal, or using adequate contraceptive measures. Continuing use of antihypertensive medication and thyroid hormone replacement therapy was permitted provided that the dose had been stable for at least 3 months before entry into the study. Similarly, patients receiving oral estrogen, oral contraceptives, or transdermal estrogen replacement therapy were allowed into the study if the dose had been stable for at least 6 weeks before the initial study visit. Patients continuing into the treatment phase were required to have demonstrated compliance of ≥75% with study medication during the placebo run-in phase.
In an effort to have a population of patients with a stable weight, patients were excluded from the study if they had lost >3 kg or had taken part in a formal weight-loss program 3 months before screening. Additional exclusion criteria included elevated lipid levels resulting from a concurrent medical condition (other than obesity), drug therapy, or alcoholism. Patients were also excluded if they had a systolic blood pressure >140 mm Hg or a diastolic blood pressure >90 mm Hg, supine pulse rate >95 beats/min, a history of a medical condition affecting a major organ system, cancer, cardiovascular disease (except for controlled hypertension), cerebrovascular disease, seizure disorder, diabetes mellitus, intolerance to central nervous system stimulants, hypersensitivity to 2 or more classes of drugs, significant psychologic dysfunction, and recent drug or alcohol addiction.
Efficacy and safety assessments
Weight-related efficacy measurements included body weight (recorded at each visit), waist and hip circumferences (recorded at baseline and at weeks 12 and 24), and BMI (calculated at each visit). Serum triglycerides (TG), HDL-C, low-density lipoprotein cholesterol (LDL-C), and total cholesterol (TC) levels were measured at baseline and at weeks 8, 12, 16, 20 , and 24 after a 12-hour fast by standardized automated enzymatic methods at a National Heart, Lung, and Blood Institute-Centers for Disease Control and Prevention regional network reference lipid laboratory. The LDL-C level was calculated with the Friedewald formula (LDL = TC -HDL -[TG/5]). 32 The following quality-of-life measures were administered at baseline, week 12, and week 24: (1) the Impact of Weight on Quality of Life (IWQOL) Questionnaire 33 and (2) the Medical Outcomes Study (MOS) Short Form Health Survey (SF-36). 34 The IWQOL Questionnaire consists of 8 scales: (1) Health, (2) Social/Interpersonal, (3) Work, (4) Mobility, (5) Self-esteem, (6) Sexual Life, (7) Activities of Daily Living, and (8) Measurements obtained at the baseline visit were reported as the baseline values for all efficacy assessments, with the exception of serum lipid levels. For all serum lipid levels baseline values were the means of 3 measurements taken at the baseline visit and at the placebo run-in visits (weeks -2 and -1).
Vital signs (sitting pulse rate, diastolic blood pressure, and systolic blood pressure) were measured at each visit. Adverse events were recorded throughout the study. Routine laboratory tests were performed at baseline and weeks 12 and 24; thyroid profiles were performed at baseline and week 24. Patients were not followed up after the study.
Statistical analyses
For all results, last-observation-carried-forward (LOCF) data are reported. Patients had to have a baseline assessment and at least one on-treatment assessment to be included in the analysis. A sample size of 150 patients per treatment group (300 total) was necessary to show an α level of .05 and 90% power. All statistical tests were 2 tailed at the .05 level of significance. A 2-way analysis of variance model on ranked data was used to analyze the changes from baseline on all patients for the LOCF data set. Five percent and 10% weightloss responder analyses of lipid data were performed with the Kruskal-Wallis test. Comparison of the frequencies of patients achieving 5% and 10% weight loss was performed the Fisher exact test.
Results
Patient demographics
No significant differences in baseline characteristics were observed between treatment groups (Table I) . Although not shown in Table I , treatment groups were also similar in their history of tobacco and alcohol use.
Weight and related parameters
After 24 weeks of treatment, patients receiving sibutramine lost an average of 4.9 kg from baseline compared with 0.6 kg among patients receiving placebo (P ≤ .05, Table II ). Mean weight loss among patients receiving sibutramine was significantly greater than that among patients receiving placebo at the earliest time point (week 2) and at all subsequent time points ( Figure 1 ). Among patients receiving sibutramine, there were significantly greater proportions of patients who lost ≥5% and ≥10% of their baseline weight (5% and 10% responders) compared with the placebo group (P Percentage of patients in the sibutramine and placebo groups losing ≥5% and ≥10% of baseline weight (5% responders and 10% responders). P ≤ .05 for sibutramine versus placebo for both categories.
≤ .05, Figure 2 ). Patients receiving sibutramine also had significant decreases in BMI (-1.7), waist circumference (-5.6 cm), and hip circumference (-3.3 cm) compared with patients receiving placebo (P ≤ .05, Table II) .
Serum lipids
Combined, the 5% and 10% weight-loss responders in the sibutramine group had significantly greater (P < .05) decreases in mean TG levels compared with all patients receiving placebo (Figure 3) . At week 24, a mean decrease in TG levels of 33.4 mg/dL was observed among 5% weight-loss responders to sibutramine and 72.3 mg/dL among 10% weight-loss responders to sibutramine, whereas mean TG levels decreased by 38.5 mg/dL and 29.2 mg/dL, respectively, among 5% and 10% responders receiving placebo (P ≤ .05 for 5% responders). The mean TG level among all patients receiving sibutramine decreased compared with that for all patients receiving placebo but did not reach statistical significance (P = .14).
Patients receiving sibutramine had significant improvements in HDL-C levels. The mean level of HDL-C among all patients receiving sibutramine increased by 3.8 mg/dL at week 24 compared with a mean increase of 1.7 mg/dL among all patients receiving placebo (P ≤ .05, Figure 4 ). Even greater mean increases in HDL-C levels were found among 5% and 10% responders in the sibutramine group (P ≤ .05, Figure 4 ).
Patients treated with sibutramine who lost ≥10% of their baseline weight demonstrated a mean reduction in the serum TC level of 13.8 mg/dL, whereas all patients treated with placebo had a mean increase of 7.2 mg/dL (P ≤ .05, Table III) . The mean TC level among all patients receiving sibutramine and among 5% responders to sibutramine was not significantly different from than that for all patients receiving placebo. No statistically significant differences in mean LDL-C were found between patients receiving sibutramine and patients receiving placebo (Table III) in this population of patients with hypertriglyceridemia (see Discussion).
Correlations between weight loss and observed serum TG and HDL-C changes were demonstrated for sibutramine-treated and placebo-treated patients (P ≤ .05), indicating that, in general, improvements in serum lipids are proportional to the degree of weight loss, whether that weight loss occurs with sibutramine or placebo ( Figure 5 ).
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Figure 3
Mean change from baseline in serum TG levels for all patients receiving sibutramine or placebo and for 5% and 10% responders in the sibutramine and placebo groups. P ≤ .05 versus all patients receiving placebo for the 5% and 10% responders to sibutramine. n, Number of patients in each responder category.
Figure 4
Mean change from baseline in serum HDL-C for all patients receiving sibutramine or placebo and for 5% and 10% responders in the sibutramine and placebo groups. P ≤ .05 versus all patients receiving placebo for all patients receiving sibutramine and for the 5% and 10% responders to sibutramine. n, Number of patients in each responder category. 
Safety and tolerability
Most adverse events reported by patients receiving sibutramine or placebo were mild to moderate. The most common (≥10%) adverse events experienced by patients during this study are shown in Table V . The incidence of most of these adverse events was similar for patients receiving sibutramine and placebo, with the exception of dry mouth, constipation, and nausea.
Patients receiving sibutramine had a mean increase in systolic blood pressure of 4.0 mm Hg, but this increase was not significantly different from that among patients receiving placebo (2.0 mm Hg). The mean increase in diastolic blood pressure reported for patients receiving sibutramine (3.6 mm Hg) was statistically significantly greater than that for patients receiving placebo (1.0 mm Hg, P ≤ .05). Patients receiving sibutramine also had statistically significant increases in mean pulse rate compared with placebo-treated patients (6.8 vs 0.1 beats/min, P ≤ .05).
Similar proportions of patients in the sibutramine and placebo groups discontinued treatment (29.6% of the sibutramine group vs 33.8% of the placebo group, Table V) . None of the patients receiving sibutramine discontinued treatment owing to lack of efficacy. Sixteen patients (9.9%) receiving sibutramine and 11 patients (6.9%) receiving placebo were discontinued from treatment because of an adverse event. Four patients were discontinued from treatment because of worsening hypertension (1 patient receiving sibutramine [0.6%] and 3 patients receiving placebo [1.9%]). One patient receiving sibutramine had a serious adverse event (cholecystitis) that was considered to be possibly related to treatment.
Discussion
Although overweight and obese patients have been shown to have a greater risk of CVD, clinical trials in this population have consistently demonstrated that modest weight loss (5% to 10% of body weight) is accompanied by clinically significant improvements in comorbid risk factors such as dyslipidemia. 11, 12, 35, 36 However, even this degree of weight loss is difficult to sustain through lifestyle changes alone. Although the main goal of medical therapy for obesity is to decrease mortality, morbidity, and costs associated with obesity, a more proximate goal has increasingly become defined as a sustainable 5% to 10% decrease in body weight. [35] [36] [37] Along with body weight, waist circumference, which is an indicator of the amount of visceral fat that has been linked to comorbid conditions such as CVD, 38, 39 is a strong predictor of morbidity.
The results of this study demonstrate the efficacy of Table V . Most common* adverse events and reasons for discontinuation sibutramine for inducing weight loss and decreasing waist circumference. Sibutramine was also efficacious at improving serum levels of triglycerides and HDL-C in the overweight and obese patients with high serum TG and low serum HDL-C levels who lost weight in this study. Patients who lost weight successfully (ie, 5% responders) on sibutramine had improvements in their serum lipid levels that were similar in magnitude to those observed in patients who successfully lost weight on placebo. The advantage of sibutramine in this regard was that many more patients lost weight successfully on sibutramine than on placebo, so many more patients on sibutramine had improvements in their serum lipid levels. The all-placebo group was chosen as the reference for these comparisons because the average weight of this group remained essentially unchanged during
Figure 5
Change from baseline in serum lipids versus change from baseline in body weight. All sibutramine slopes are statistically significantly different from 0 (P ≤ .05), except for the LDL-C slope. None of the sibutramine slopes are statistically significantly different from the placebo slopes.
the study, thus providing a control for time and treatment effects while leaving weight loss as a variable. High serum TG and low serum HDL-C levels are strongly correlated with the degree of obesity and increase the risk of CVD. [6] [7] [8] 40 Improving this dyslipidemic pattern without changes in LDL-C has been shown to significantly reduce cardiovascular morbidity and mortality. [41] [42] [43] However, there are no published controlled studies directly demonstrating improvement in cardiovascular outcome independently related to weight loss intervention. A decrease in weight and the associated favorable effects on lipid levels are intermediate biomarkers and do not necessarily imply improved cardiovascular outcome. This consideration is particularly important in the setting of a pharmacotherapy such as sibutramine, which also has adverse cardiovascular effects (see below). Long-term prospective studies with morbidity and mortality end points will be needed to address the overall benefit/risk ratio of sibutramine or other weight loss agents, particularly in the setting of known coronary artery disease.
In this study TC and LDL-C levels did not decrease significantly with sibutramine treatment in the population of patients with hypertriglyceridemia and normal LDL-C levels studied. This lack of appreciable effect on TC and LDL-C levels was expected because successful treatment of low HDL-C levels and hypertriglyceridemia often does not result in decreased LDL-C levels in patients with normal LDL-C levels (increased clearance of very-low-density lipoprotein cholesterol levels results in increased production of LDL-C). [44] [45] [46] In patients who do not have hypertriglyceridemia, sibutramine lowers TC and LDL-C levels. 31 Treatment with sibutramine was generally well tolerated in this study. Most adverse events were mild to moderate, with a similar incidence observed among sibutramine-treated and placebo-treated patients. Rates of discontinuation because of adverse events and all causes were similar among patients receiving sibutramine and patients receiving placebo. For patients receiving sibutramine, small mean increases in systolic (2.0 mm Hg, placebo corrected) and diastolic (2.6 mm Hg, placebo corrected) blood pressure were observed. Because of the potential adverse consequence of these effects, long-term prospective studies with morbidity and mortality end points are needed.
Conclusions
Sibutramine 20 mg once daily given to patients with obesity and dyslipidemia induced statistically and clinically significant weight loss that was accompanied by significant improvements in serum TC and HDL-C levels without serious, therapy-limiting adverse events. Consequently, sibutramine may be indicated as an adjunct to dietary therapy in overweight or obese patients with dyslipidemia.
